Pasithea Therapeutics Corp.
NASDAQ Capital MarketRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Pasithea Therapeutics Corp. (Nasdaq: KTTA) is a clinical-stage biotechnology company focused on the discovery, research and development of innovative treatments for central nervous system (CNS) disorders, RASopathies and oncology indications. Founded in 2020 and headquartered in Miami Beach, Florida, the company advances a pipeline of proprietary therapeutic candidates targeting neuroinflammatory and MAPK pathway-driven diseases, with primary operations conducted in the United States. Its lead product candidate, PAS-004, comprises a next-generation macrocyclic mitogen-activated protein kinase (MEK) inhibitor for neurofibromatosis type 1 (NF1)-associated plexiform neurofibromas, MAPK pathway-driven tumors including BRAFv600 and BRAF fusion tumors, ETS2-driven diseases such as inflammatory bowel disease, primary sclerosing cholangitis and ankylosing spondylitis, as well as other solid tumors; PAS-003 targets amyotrophic lateral sclerosis; and PAS-001 targets schizophrenia. The company conducts Phase 1 clinical trials of PAS-004 in advanced cancer patients (NCT06299839) and a Phase 1/1b trial in NF1-associated plexiform neurofibromas (NCT06961565), reporting positive pharmacodynamic results including up to 91% pERK inhibition, stable disease and tumor shrinkage in pancreatic cancer patients as of late 2025. In December 2025, Pasithea closed a $60 million public offering of common stock led by healthcare investors including Vivo Capital, Janus Henderson Investors and others, extending its cash runway through at least mid-2028 to support ongoing clinical development and corporate purposes; it completed Cohort 7 dosing in the PAS-004 Phase 1 trial in November 2025 and filed an S-1/A in late November for up to 75 million shares and warrants targeting approximately $54.9 million.
Pasithea Therapeutics Announces Positive Interim Phase 1 Advanced Cancer Study Data Demonstrating Long-Term Safety and Tolerability, and Durable Clinical Activity in MEK/BRAF-Pretreated Patients, plus Protocol Expansion
Pasithea Therapeutics Announces Amendments to Clinical Study Protocol for Phase 1/1B NF1 Clinical Trial
Pasithea Therapeutics Announces Exhibit at Children's Tumor Foundation 2026 NF Conference
Pasithea Therapeutics (KTTA) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
Pasithea Therapeutics Announces Orphan Drug Designation by FDA of PAS-004 for Treatment of Amyotrophic Lateral Sclerosis (ALS)
Pasithea Therapeutics Announces Appointment of Kartik Krishnan, M.D., Ph.D. as Chief Medical Officer
Pasithea Therapeutics Announces Appointment of Kartik Krishnan, M.D., Ph.D. as Chief Medical Officer
Pasithea Therapeutics Announces Grant of Fast Track Designation by FDA to PAS-004 for Treatment of Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) Causing Significant Morbidity
Pasithea Therapeutics (KTTA) Expected to Announce Quarterly Earnings on Monday
Pasithea Therapeutics Corp. (KTTA) Presents at Oppenheimer 36th Annual Healthcare Life Sciences Conference Transcript
Pasithea Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference
Pasithea Therapeutics Provides Outlook on PAS-004 Clinical Programs and Data Release Timelines
Pasithea Therapeutics Announces Closing of $60 Million Public Offering of Common Stock
Pasithea Therapeutics Announces Pricing of $60 Million Public Offering of Common Stock
Pasithea Therapeutics Announces $1 Million Award by ALS Association to Study the Efficacy, Safety, and Tolerability of PAS-004 for Treatment of ALS
Pasithea Therapeutics Announces Completion of Cohort 7 in Ongoing Phase 1 Trial of PAS-004 in Advanced Cancer Patients, with Positive Safety, Pharmacokinetic (PK), and Pharmacodynamic (PD) Data
Pasithea Therapeutics (NASDAQ:KTTA) Shares Down 29.6% – Should You Sell?
Pasithea Therapeutics Announces Positive PAS-004 Tablet Pharmacokinetic (PK) Data in Ongoing Phase 1/1b Trial in Adult NF1 Patients
Pasithea Therapeutics Announces Positive Phase 1 Data Including Partial Response, Demonstrating Monotherapy Clinical Activity and Favorable Safety Profile for PAS-004 in Advanced Cancer Study
Pasithea Therapeutics Announces Activation of Clinical Trial Site at University of Alabama at Birmingham for Ongoing Phase 1/1b Trial of PAS-004 in Adult NF1 Patients